# NuCana BioMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nucana-biomed

- Industry: Pharmaceuticals
- Headquarters: Edinburgh, UK
- Website: www.nucanabiomed.com
- Total disclosed funding: $67M
- Latest round: Series B (Mar 31, 2014)
- Investors on record: 5

## About

NuCana BioMed Limited is a biotechnology firm focused on developing innovative cancer therapies utilizing its proprietary ProTide technology to improve the efficacy and safety of existing treatments.Founded in 2008 and headquartered in Edinburgh, UK, NuCana BioMed Limited is dedicated to the advancement of cancer treatment options. The company's approach involves leveraging its proprietary ProTide technology to enhance existing drugs. In September 2017, the firm raised USD 100 mn through an IPO, underscoring its commitment to expanding its therapeutic pipeline. The current CEO, Hugh Griffith, has a background in biotechnology and has previously founded other ventures in the pharmaceutical sector.NuCana BioMed Limited specializes in developing novel cancer therapies that utilize its proprietary ProTide technology. This innovative platform is designed to improve the treatment outcomes of existing cancer medications, ensuring better efficacy and safety for patients. The firm targets various cancer types and aims to provide therapies that address significant unmet medical needs in oncology.In the most recent reporting year of 2015, NuCana BioMed Limited reported zero revenue, and as of 2023, the EBITDA stood at USD -40,065,906.70. This reflects the company's investment in research and development as it seeks to bring its innovative therapies to market.Following its IPO in September 2017, where it raised USD 100 mn by selling 6.7 million shares at USD 15 per share, NuCana BioMed Limited plans to utilize these funds to accelerate the development of its ProTide technology and expand its clinical trials. The company is focused on launching new products targeting various cancer indications, with a strategic aim to extend its market reach into North America and Europe by 2025. The funding will primarily support further research and development efforts to bring its promising therapies to patients.

## Funding rounds

- Series B, Mar 31, 2014, $57M — Sofinnova Partners, Sofinnova Investments, 5Y Capital, Alida Capital International, Scottish Enterprise
- Series A, Nov 24, 2011, $11M — Sofinnova Partners, 5Y Capital, Alida Capital International, Scottish Enterprise

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B
- Alida Capital International — Series A, Series B
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B